X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$1.06 USD
-0.05 (-4.50%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $1.06 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
X4 Pharmaceuticals, Inc. [XFOR]
Reports for Purchase
Showing records 81 - 93 ( 93 total )
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
X4 Analyst Day Presentations Suggest Greater Commercial Potential in WHIM
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on the Analyst Day in April; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on the Analyst Day in April; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Update - Multiple Clinical Catalysts and Inaugural R-D Day in 2020
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Patent Strenghtens Mavorixafor''s Commercial Outlook. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Breaking Free From WHIMs; Initiate With Buy and a $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Waldenstrom''s Study Initiated and Initial Data Remains on Track For 2H20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $20 price target
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z